Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalated daunorubicin induction and gemtuzumab ozogamicin maintenance in older AML/RAEB patients
NL-OMON21122Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Oct 2000
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daunorubicin, cytarabine and gemtuzumab ozogamicin in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (4 arms), sponsored by HOVON. Primary endpoints: Event-free survival and Disease-free survival. Started Oct 2000; status: active, not recruiting.
02
Drugs
daunorubicincytarabinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on NL-OMON21122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21122.